Next 10 |
home / stock / paicw / paicw news
NEW YORK and SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW) (“Perta”), a publicly traded special purpose acquisition company, announced today that it has entered into certain backstop agreements and forward share purchas...
-The Definitive Proxy Statement Has Been Filed with The Securities and Exchange Commission- -Stockholders Special Meeting Scheduled for January 6, 2022- NEW YORK and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW ...
- Dr. Bellanti is Director of the International Center for Interdisciplinary Studies of Immunology and Professor of Pediatrics and Microbiology and Immunology at Georgetown University SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical...
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today the site initiation for its Pha...
- Dr. Catherine Blish is Professor of Medicine and Immunology and Associate Dean for Basic and Translational Research at the Stanford University School of Medicine – - Dr. Paul Spearman is Director of the Infectious Disease Division at Cincinnati’s Children...
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today the initiation for its Phase 1b...
-REVID may have use by individuals in at-home settings for rapid monitoring of respiratory viral infections- -Offering broad detection of various viral infections, such as SARS-CoV-2, RSV, and influenza, institutions could potentially use REVID for mass screening and pre-PCR s...
-Anti-viral nasal drop REVTx-99 has potential to broadly prevent or treat respiratory infections including influenza, SARS-CoV-2, rhinovirus, RSV and pneumonia- -Intranasal immunomodulator, REVTx ‑ 200, would be used in combination with an intramuscular vaccinat...
-Phase 1b study will investigate the efficacy of REVTx-99 on nasal symptoms elicited by nasal allergen challenge- -Top-line data anticipated in the first quarter of 2022- SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage ...
- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life...
News, Short Squeeze, Breakout and More Instantly...
Petra Acquisition Inc. Warrant Company Name:
PAICW Stock Symbol:
NASDAQ Market:
NEW YORK and SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW) (“Perta”), a publicly traded special purpose acquisition company, announced today that it has entered into certain backstop agreements and forward share purchas...
-The Definitive Proxy Statement Has Been Filed with The Securities and Exchange Commission- -Stockholders Special Meeting Scheduled for January 6, 2022- NEW YORK and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW ...
- Dr. Bellanti is Director of the International Center for Interdisciplinary Studies of Immunology and Professor of Pediatrics and Microbiology and Immunology at Georgetown University SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical...